Advaxis Finds Alternative Funding In Animal Health Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Advaxis has teamed up with pet therapeutics company Aratana to develop its human immunotherapy in companion animal indications and intends to use the funding to further human clinical development.
You may also be interested in...
Ahead Of Schedule, Pfizer Prepares To Set Zoetis Free In Stock Swap
The Big Pharma intends to loosen its leash on its former animal health business come June when Pfizer shareholders will be given an option to swap their shares for Zoetis stock. Meanwhile, Pfizer continues its strategy to shift its focus back to the core pharmaceutical business.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.